Aileron Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
30 juil. 2019 19h03 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other...
Aileron Therapeutics to Report Second Quarter 2019 Financial Results on August 6, 2019
30 juil. 2019 16h47 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other...
Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy
27 juin 2019 08h00 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other...
Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach
24 juin 2019 08h00 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other...
Aileron Therapeutics to Present at the Jefferies 2019 Healthcare Conference
30 mai 2019 08h00 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other...
Aileron Therapeutics Reports First Quarter 2019 Financial Results
08 mai 2019 16h57 HE
|
Aileron Therapeutics, Inc.
Aileron announced a $26 million capital raise via PIPE transaction Enrollment in Phase 2a expansion cohort testing ALRN-6924 in combination with Pfizer’s IBRANCE® (palbociclib) in MDM2-amplified...
Aileron Therapeutics to Report First Quarter 2019 Financial Results on May 8
01 mai 2019 18h31 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other...
Aileron Therapeutics Completes $26M Private Placement
03 avr. 2019 12h15 HE
|
Aileron Therapeutics, Inc.
Satter Medical Technology Partners led the private placement; Dr. Nolan Sigal, Partner at Satter Management, joins Aileron’s Board of Directors WATERTOWN, Mass., April 03, 2019 (GLOBE NEWSWIRE) --...
Aileron Therapeutics Announces Pricing of $26M Private Placement
29 mars 2019 09h00 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other...
Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer
04 mars 2019 09h00 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other...